Stellantis N.V. Common Shares vs TransMedics Group Inc — how do they compare? Stellantis N.V. Common Shares trades at $4.25 (market cap $16.20B), while TransMedics Group Inc trades at $75.3 (market cap $2.62B). The key difference: Stellantis N.V. Common Shares is far larger — about 6.2× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Stellantis N.V. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Stellantis N.V. Common Shares for 0 Days and TransMedics Group Inc for 24 Days on average.
| STLA | TMDX | |
|---|---|---|
Market Cap | $16.20B | $2.62B |
Volume | 30,607,418 | 891,435 |
Sector | Consumer Cyclical | Health |
52-Week High | $12.12 | $150.42 |
52-Week Low | $4.27 | $61.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $35.94B | $3.01B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TransMedics Group (TMDX) trades at $79.135, up 1.23% on the day, but faces a bearish technical signal with recent earnings misses in Q1 and Q2 2026. The company maintains strong profitability with a 58.69% gross margin and 22.69% net margin, though net income is projected to decline in 2026. Recent news highlights insider buying and CFO appointment, but also ongoing legal investigations into fiduciary duties.
The stock presents a mixed outlook; analyst consensus is bullish with a $99.63 price target, but risks include margin pressure from heavy investment and legal overhangs. Upside hinges on execution against guidance, while downside is cushioned by solid cash flow and institutional support.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Stellantis N.V. is a multinational automaker formed from the 2021 merger of Fiat Chrysler Automobiles and PSA Group, manufacturing vehicles under brands including Jeep, Ram, Chrysler, Dodge, Fiat, Peugeot, and Citroën.
Read more on STLA →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →